drugset / Trial / NCT05605470
Immunogenicity and Safety of ChulaCov19 BNA159 and ChulaCov19 BNA159.2 Vaccines as a Booster Dose in Adults
Phase 2
Completed
150 enrolled
Technovalia, Pty Ltd
BioNet-Asia Co., Ltd. · collabChulalongkorn University · collabSouthern Star Research · collab
RandomizedParallel-groupOpen-labelPrevention
Summary
This clinical trial is designed to assess the safety, tolerability and immunogenicity of a single dose of ChulaCov19 BNA159 and ChulaCov19 BNA159.2 vaccines as a booster dose, given at least 3 months after receipt of a previous booster dose of any authorized/approved COVID-19 vaccine.
Timeline
- Start
- 2023-01-19
- Primary completion
- 2024-07-15
- Completion
- 2024-11-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | COMVIGEN | Vaccine | 50 ug | Intramuscular |
| Subject | COMVIGEN | Vaccine | 0.5 ml | Intramuscular |
| Subject | ChulaCov19 BNA159 | Messenger RNA (mRNA) | 50 ug | Intramuscular |
| Subject | ChulaCov19 BNA159 | Messenger RNA (mRNA) | 0.5 ml | Intramuscular |
| Comparator | Pfizer/BNT | Vaccine | 30 ug | Intramuscular |
| Comparator | Pfizer/BNT | Vaccine | 0.3 ml | Intramuscular |